Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 89 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Researchers Have Harnessed a Compound from a Common Plant Called Feverfew... August 2, 2019 New on NCI’s Websites for December 2022 December 27, 2022 Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole... August 11, 2021 ‘Jeopardy!’ Legend James Holzhauer Donates Portion Of Winnings To Cancer Walk... June 24, 2019 Load more HOT NEWS PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... Breast Cancer Patients With Anxiety or Depression More Prone to Opioid... ESMO Immuno-Oncology Virtual Congress 2020 Scientists Focus on Fusion Proteins in Childhood Cancers
